Showing 8161-8170 of 9130 results for "".
- DermBiont Acquires Chromadermhttps://practicaldermatology.com/news/dermbiont-acquires-chromaderm/2461017/
- Data Demonstrate Safety, Efficacy of Dupilumab for AD in Patients as Young as Six Monthshttps://practicaldermatology.com/news/data-demonstrate-safety-efficacy-of-dupilumab-for-ad-in-patients-as-young-as-six-months/2461005/Data demonstrating the safety and efficacy of Sanofi and Regeneron’s
- Alastin to be Acquired by Galdermahttps://practicaldermatology.com/news/alastin-to-be-acquired-by-galderma/2460997/Galderma is set to acquire Alastin Skincare®, Inc. The world’s largest independent dermatology company has signed a definitive agreement to acquire the specialty aesthetics company dedicated to developing innovative and clinically-tested physician-dispensed skincare products. Financial
- ASDSA Honorees Recognized for Engagement in Initiatives that Benefit Dermatologic Surgery and Patientshttps://practicaldermatology.com/news/asdsa-honorees-recognized-for-engagement-in-initiatives-that-benefit-dermatologic-surgery-and-patients/2460995/The American Society for Dermatologic Surgery Association (ASDSA) announced the recipients of its annual awards this week during the ASDS / ASDSA Virtual Annual Meeting. ASDSA is proud to recognize its members who contribute significant time and expertise advocating for patient safety,
- Almirall US Supports The Skin Cancer Foundation’s Mobile Skin Cancer Screening Programhttps://practicaldermatology.com/news/almirall-us-supports-the-skin-cancer-foundations-mobile-skin-cancer-screening-program/2460983/Almirall US is supporting The Skin Cancer Foundation’s mobile skin cancer screening program, Destination Healthy Skin. The Destination Healthy Skin RV travels to cities across the US, where local volunteer dermatologists provide free full-body skin cancer screenings in private exam rooms ab
- Skyrizi Improves PsA Signs and Symptomshttps://practicaldermatology.com/news/skyrizi-improves-psa-signs-and-symptoms/2460981/AbbVie’s risankizumab (SKYRIZI) showed greater improvements in psoriatic arthritis (PsA) signs and symptoms compared to treatment with placebo at week 24 in two Phase 3 clinical trials, according to research slated to be presented American College of Rheumatology (ACR) Convergence 2021.
- St. Ives Launches Social Media Contest to Help Reduce College Students' Financial and Skin Stresshttps://practicaldermatology.com/news/st-ives-launches-social-media-contest-to-help-reduce-college-students-financial-and-skin-stress/2460961/
- FDA Approves Cyltezo as First Interchangeable Biosimilar with Humirahttps://practicaldermatology.com/news/fda-approves-cyltezo-as-first-interchangeable-biosimilar-with-humira/2460957/The FDA approved the supplemental Biologics License Application (sBLA) for Boehringer Ingelheim's Cyltezo (adalimumab-adbm) as the first Interchangeable biosimilar with Humira (adalimumab). The FDA originally approved Cyltezo in 2017 for the treatment of multiple chronic inflammatory diseases
- Reistone’s Topical JAK Inhibitor Performs Well in Mild to Moderate ADhttps://practicaldermatology.com/news/reistones-topical-jak-inhibitor-performs-well-in-mild-to-moderate-ad/2460951/Reistone Biopharma’s SHR0302 ointment performed well in a Phase 2 study of patients with mild-to-moderate atopic dermatitis (AD), the company reports. SHR0302 ointment, a topical, selective JAK1 inhibitor, met key primary and secondary endpoints, demonstrating significant improvem
- Topline Phase 2b Data Promising for Timber's Topical Isotretinoin in CIhttps://practicaldermatology.com/news/topline-phase-2b-data-promising-for-timbers-topical-isotretinoin-in-ci/2460946/Top-line data from Timber Pharmaceuticals’ Phase 2b CONTROL study show “clinically meaningful efficacy with a favorable safety profile” for investigational topical isotretinoin, says the company’s Chairman and CEO John Koconis. TMB-001 is formulated using